Who
Jeffrey P. George
Director
Company insider
Files Form 4 as: Director, LENZ Therapeutics; Director, Amneal Pharmaceuticals; Director, 908 Devices.
In numbers
- Trades disclosed
- 59
- Buys
- 2
- Sells
- 0
- Bought
- $199K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 14 Dec 2019
- Last trade
- 15 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 15 Jun 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 15 Jun 2026filed 15 Jun 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —34,819 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —34,819 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —34,819 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —34,819 | filing |
| 6 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,824 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,824 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K5,592 at $8.92 | filing |
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K5,592 at $8.92 | filing |
| 12 Jun 2025filed 13 Jun 2025 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —14,083 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,516 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code M | —11,364 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | MASS 908 DevicesLife-science tools | SEC FORM 4 Code M | —11,364 | filing |
| 11 Jun 2025filed 11 Jun 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —34,819 at $0.00 | filing |
| 5 May 2025filed 8 May 2025 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,258 at $0.00 | filing |
| 5 May 2025filed 8 May 2025 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —40,258 | filing |
| 13 Jun 2024filed 14 Jun 2024 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —11,364 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —15,996 at $0.00 | filing |
News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Average Target Price of $28.80LENZ · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Jeffrey P. George; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.